Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US90400D1081
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG001RWPDW6
RARE
Ultragenyx Pharmaceutical Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Ultragenyx Pharmaceutical Inc
ISIN
US90400D1081
TICKER
RARE
MIC
XNAS
REUTERS
RARE.OQ
BLOOMBERG
RARE US
Sa., 21.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW ORLEANS, March 20, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NasdaqGS: RARE), if they purchased or otherwise acquir...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Fr., 20.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NOVATO, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 10,839 restricted stock units of the company’s common stock to two newly hired non-executive...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Fr., 20.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Fr., 20.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, March 19, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusi...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 19.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 19.03.2026       Ultragenyx Pharmaceutical
US90400D1081

SAN DIEGO, March 19, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, all dates inclusive (the "Class Period"), have until Monday, April 6, 2026 to seek appointment as lead plaintiff of the Ultragen...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 18.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 18.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Know Your Rights: How Basic Inc. v. Levinson Enables Investor RecoveryNEW YORK, March 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)....
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Di., 17.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Di., 17.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are enc...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 16.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purc...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 16.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 16.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Philadelphia, Pennsylvania--(Newsfile Corp. - March 16, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased Ultragenyx common stock during the period from August 3, 2023...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
So., 15.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Sa., 14.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK and NEW ORLEANS, March 13, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NasdaqGS: RARE) of a class action securities lawsuit.   CLASS DEFINI...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Fr., 13.03.2026       Ultragenyx Pharmaceutical
US90400D1081

SAN DIEGO, March 13, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), have until Monday, April 6, 2026 to seek appointment as lead plaintiff of the Ul...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Fr., 13.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purc...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Ultragenyx Pharmaceutical
US90400D1081

LOS ANGELES, March 12, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated there...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Ultragenyx Pharmaceutical
US90400D1081

LOS ANGELES, March 12, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commissi...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 12.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purc...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 11.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 11.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Important Information Regarding Section 20(a) Individual Liability ClaimsRARE INVESTOR ALERTNEW YORK, March 11, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) of a pending securities class action. To be considered for lead plaintiff, investors must file by April 6, 2026....
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Di., 10.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purc...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Di., 10.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Di., 10.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, March 10, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are enc...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, March 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusiv...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Philadelphia, Pennsylvania--(Newsfile Corp. - March 9, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased Ultragenyx common stock during the period from August 3, 2023...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purch...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
So., 08.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Did you buy RARE common stock between August 3, 2023, and December 26, 2025?Affected Ultragenyx Pharmaceutical Inc. Investor SummaryWho: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)What: Securities fraud class action lawsuit filedClass Period: August 3, 2023, through December 26, 2025Deadline to Seek Lead Plaintiff Status: April 6, 2026Key Lawsui...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
So., 08.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
So., 08.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purch...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Sa., 07.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW ORLEANS, March 6, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NasdaqGS: RARE), if they purchased or otherwise acquire...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Sa., 07.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purch...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Fr., 06.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Fr., 06.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 05.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, March 5, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire b...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 05.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purch...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 04.03.2026       Ultragenyx Pharmaceutical
US90400D1081

SAN DIEGO, March 4, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, both dates inclusive (the "Class Period"), have until Monday, April 6, 2026 to seek appointment as lead plaintiff of the Ultragen...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 04.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Alert: Claims Focus on Alleged Misrepresentations About Setrusumab Efficacy PotentialNEW YORK, March 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) securities of a pending securities class action. Investors have until April 6, 2026 to seek lead plaintiff status....
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Di., 03.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, March 3, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusiv...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Di., 03.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, March 3, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are enco...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Di., 03.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 02.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Did you buy RARE common stock between August 3, 2023, and December 26, 2025?Affected Ultragenyx Pharmaceutical Inc. Investor SummaryWho: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)What: Securities fraud class action lawsuit filedClass Period: August 3, 2023, through December 26, 2025Deadline to Seek Lead Plaintiff Status: April 6, 2026Key Lawsui...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 02.03.2026       Ultragenyx Pharmaceutical
US90400D1081

LOS ANGELES, March 2, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereu...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 02.03.2026       Ultragenyx Pharmaceutical
US90400D1081

LOS ANGELES, March 2, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commis...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
So., 01.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Sa., 28.02.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - February 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Sa., 28.02.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK and NEW ORLEANS, Feb. 27, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NasdaqGS: RARE) of a class action securities lawsuit.   CLASS DEFINIT...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Fr., 27.02.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - February 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink